The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

Despite these limitations, the findings suggest that GLP-1 receptor agonists may provide important limb, cardiovascular, and renal protection in patients with diabetes and prior MALEs, supporting ...

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

Risk of recurrent major adverse limb events was lower in diabetes patients taking GLP-1 agents compared with DPP-4 inhibitors. Reduction of limb events was most significant for major amputations, ...

Please provide your email address to receive an email when new articles are posted on . In patients with diabetes and major adverse limb events, GLP-1s conferred better outcomes than DPP-IV inhibitors ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication for weight loss and diabetes, um, is associated with *** lower risk of ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Interest in the use and impacts of glucagon-like peptide-1 receptor agonists in rheumatology has exploded over the past year, a trend that appeared to crescendo at ACR Convergence 2025. There, ...

GLP 1 receptor agonists were associated with higher incident chronic cough in adults with type 2 diabetes, with risk persisting even after excluding patients with reflux diagnoses.